Side effects of CDK46 inhibitors, dosing schedules, and second-line treatment options for ERPR positive metastatic breast cancer

This chapter discusses the side effects and monitoring requirements of CDK46 inhibitors, different dosing schedules, and the shift in treatment preference for patients in visceral crisis. It also mentions second-line options for ERPR positive metastatic breast cancer.